菜单

Press Releases

WuXi Biologics Congratulates Fred Ramsdell, PhD, Co-Founder and Scientific Advisory Board Chair of its Client Sonoma Biotherapeutics, on Receiving the 2025 Nobel Prize in Physiology or Medicine
October 15, 2025
WuXi Biologics Congratulates Fred Ramsdell, PhD, Co-Founder and Scientific Advisory Board Chair of its Client Sonoma Biotherapeutics, on Receiving the 2025 Nobel Prize in Physiology or Medicine

WuXi Biologics (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates Fred Ramsdell, PhD—co-founder and Chair of the Scientific Advisory Board of its client Sonoma Biotherapeutics—on being named a winner of the 2025 Nobel Prize in Physiology or Medicine. The honor recognizes Dr. Ramsdell’s work in immunotherapy and his breakthrough insights into the role of regulatory T cells (Tregs).

 

Dr. Ramsdell’s discoveries have revolutionized the field of immunology and deepened our understanding of autoimmune diseases and the important role of Tregs. Specifically, Dr. Fred Ramsdell’s work in the discovery of the gene, FOXP3, and its role in Treg development changed the field of immunology; he is a veteran biotechnology leader in immunology with nearly three decades of experience and was named along with Dr. Shimon Sakaguchi and another Sonoma Biotherapeutics co-founder, Dr. Alexander Rudensky for the 2017 Crafoord Prize – Polyarthritis.

 

Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted and durable Treg cell therapies.

 

WuXi Biologics remains committed to supporting its clients worldwide like Sonoma Biotherapeutics in advancing high-quality therapies, enabling them to succeed in the ever-evolving era of biologics and deliver impactful solutions that benefit patients worldwide.

 

About WuXi Biologics

 

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

 

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2025, WuXi Biologics is supporting 864 integrated client projects, including 24 in commercial manufacturing.

 

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

 

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

 

Contacts

 

Business

info@wuxibiologics.com

 

Media

PR@wuxibiologics.com